Patents Assigned to DeveloGen Aktiengesellschaft
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20130231283
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: February 1, 2013
    Publication date: September 5, 2013
    Applicant: DeveloGen Aktiengesellschaft
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN
    Publication number: 20130150293
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Application
    Filed: February 15, 2013
    Publication date: June 13, 2013
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventor: DEVELOGEN AKTIENGESELLSCHAFT
  • Method for treating diabetes using neurturin
    Patent number: 8399408
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: March 19, 2013
    Assignee: DeveloGen Aktiengesellschaft
    Inventors: Matthias Austen, Ulrike Burk
  • NEW FORMULATION FOR INCREASING BIOAVAILABILITY OF NEURTURIN
    Publication number: 20130053313
    Abstract: The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.
    Type: Application
    Filed: August 27, 2012
    Publication date: February 28, 2013
    Applicant: DeveloGen Aktiengesellschaft
    Inventors: Friedrich Harder, Matthias Austen
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20110003741
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: May 5, 2010
    Publication date: January 6, 2011
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100143341
    Abstract: The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: June 21, 2006
    Publication date: June 10, 2010
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Steven Taylor, Stephen Murfin, Thomas Stephen Coulter, Stefan Jakel, Babette Aicher, Arndt-Rene Kelter, Joachim Kraemer, Christian Kirchhoff, Andreas Scheel, Julian Woelcke
  • PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100105708
    Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: July 10, 2007
    Publication date: April 29, 2010
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Stefan Jäkel, Tanja Reuter, Stephen Murfin, Thomas Stephen Coulter, Steven Taylor
  • THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100056548
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: April 10, 2007
    Publication date: March 4, 2010
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Babette Aicher, Thomas Stephen Coulter, Stefan Jaekel, Arndt-René Kelter, Stephen Murfin, Tanja Reuter, Steven Taylor
  • USE OF SECRETED PROTEIN PRODUCTS FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME
    Publication number: 20090298771
    Abstract: This invention relates to the use of secreted SF01-SF13 proteins, to the use of polynucleotides encoding these, and to the use of effectors/modulators thereof in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes mellitus), obesity and/or metabolic syndrome and to the use in regeneration of tissues such as pancreatic tissues and others.
    Type: Application
    Filed: May 8, 2009
    Publication date: December 3, 2009
    Applicant: DeveloGen Aktiengesellschaft
    Inventor: Daria Onichtchouk
  • Use of a Dg147 Protein Product for Preventing and Treating Metabolic Disorders
    Publication number: 20080107639
    Abstract: The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding this in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.
    Type: Application
    Filed: January 19, 2005
    Publication date: May 8, 2008
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventor: Daria Onichtchouk
  • Method for preventing and treating diabetes using dg119
    Publication number: 20070110728
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a DG119-1 product or a DG119-1 agonist and/or an antagonist To a DG 119-2 product.
    Type: Application
    Filed: November 29, 2004
    Publication date: May 17, 2007
    Applicant: DEVELOGEN AKTIENGESELLSCHAFT
    Inventors: Matthias Austen, Daria Onichtchouk, Thomas Siegmund, Kristin Aduroja, Bettina Rudolph, Friedrich Harder
  • Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
    Publication number: 20070107073
    Abstract: The present invention discloses proteins secreted by the developing pancreas, and polynucleotides, which identify and encode these proteins. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.
    Type: Application
    Filed: November 19, 2004
    Publication date: May 10, 2007
    Applicant: DeveloGen Aktiengesellschaft
    Inventor: Daria Onichtchouk